SCIB1: Completed Phase I/II enrollment

Scancell completed enrollment of 35 patients with resected stage III/IV metastatic melanoma in an open-label, dose-escalation, U.K. Phase I/II trial evaluating 4 mg intramuscular SCIB1 given at weeks ...